Recombinant Human ANGPTL3 (C-6His)(Cat. No.:CU43) novoprotein
$90.00
In stock
SKU
CU43
10μg: $90
50μg: $250
500μg: $1050
1mg: $1500
Description
Recombinant Human Angiopoietin-related Protein 3 is produced by our Mammalian expression system and the target gene encoding Ser17-Pro220 is expressed with a 6His tag at the C-terminus.
Product Details
| Item | Details |
| Known As | Angiopoietin-related protein 3; ANGPTL3; Angiopoietin-5; ANG-5; Angiopoietin-like protein 3; ANGPT5 |
| Mol Mass | 24.6 KDa |
| APMol Mass | 30-40 KDa, reducing conditions |
| Formulation Description | Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. |
| Endotoxin | < 1 EU/µg as determined by LAL test. |
| Reconstitution | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
| Storage | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. |
Background
Angiopoietin-like 3 (ANGPTL3) is a secreted glycoprotein that is structurally related to the angiopoietins. Mature human ANGPTL3 contains an N-terminal coiled coil domain and a C-terminal fibrinogen-like domain. ANGPTL3 is expressed in the liver from early in development through adulthood. Full length ANGPTL3 circulates in the plasma as do the proteolytically separated N-and C-terminal segments containing the coiled coil domain and fibrinogen-like domains,respectively. ANGPTL3 directly inhibits lipoprotein lipase (LPL) and endothelial lipase (EL), enzymes responsible for hydrolyzing circulating triglycerides and HDL phospholipids. ANGPTL3 promotes an increase in circulating triglyceride levels without altering VLDL or HDL secretion or uptake. ANGPTL3 expression in vivo is up-regulated by LXR agonists and down-regulated by insulin, leptin, and agonists of TRβ or PPARβ.
title: A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease
authors: Hu, Xiaozhi, Fan, Jiajun, Ma, Qianqian, Han, Lei, Cao, Zhonglian, Xu, Caili, Luan, Jingyun, Jing, Guangjun, Nan, Yanyang, Wu, Tao, Zhang, Yuting, Wang, Hanqi, Zhang, Yuanzhen, Ju, Dianwen
date: 2022
journal: JOURNAL OF NANOBIOTECHNOLOGY
MDSD
Reviews
Write Your Own Review
Related Products
Check items to add to the cart or
